The results of our analysis demonstrated a noteworthy correlation between the expression of EpCAM and the overall survival (OS) of patients diagnosed with KIRC, OV, and PRAD (Fig. 3A); progression-free survival in KIRC (Fig. 3B); disease-free survival in BRCA, LUSC, TGCT, and UCS (Fig. 3C); and disease-specific survival in BLCA, COAD, KIRC, OV, and STAD (Fig. 3D). Here, EPCAM is linked to bladder transitional cell carcinoma.